Last reviewed · How we verify
NCT03543488
Neuromusuclar Adaptations in the Rheumatoid Arthritis Disease
trial testing Neuromuscular and functional capacity tests in Arthritis, Rheumatoid in 70 participants. Completed in 3 March 2014.
20 November 2013
Quick facts
| Lead sponsor | Federal University of Rio Grande do Sul |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 1 June 2013 |
| Primary completion | 20 November 2013 |
| Estimated completion | 3 March 2014 |
Drugs / interventions tested
- Neuromuscular and functional capacity tests
Conditions studied
- Arthritis, Rheumatoid — all drugs for Arthritis, Rheumatoid →
- Muscular Weakness — all drugs for Muscular Weakness →
Sponsor
Federal University of Rio Grande do Sul
Who can join
Adults 25 to 75, female only, with Arthritis, Rheumatoid or Muscular Weakness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation and progressive joint destruction. Rheumatoid cachexia is one of the structural manifestations of RA, and consists of a reduction in muscle mass, due to an increased muscle protein catabolism induced by inflammatory cytokines. This muscle mass loss generates an impairment in physical function and functional capacity in RA patients. The aim of study was to verify neuromuscular and functional responses in middle-aged women with RA compared to paired healthy women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03543488
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Arthritis, Rheumatoid
Currently open trials in the same condition.
- NCT07176390 — A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) · Phase 2 · recruiting
- NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
- NCT06528431 — Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study · Phase 4 · recruiting
- NCT06492200 — Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis · NA · recruiting
- NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting
Other Federal University of Rio Grande do Sul trials
Trials by the same sponsor.
- NCT06967493 — Effects of Amazonian Dance on Motor and Non-motor Symptoms of People With Parkinson's: Study Protocol · NA · recruiting
- NCT07470450 — Acute and Chronic Effects of Combined Training on BP in Hypertensives · NA · completed
- NCT07023146 — Effects of Different Power Training Intensities in Older Adults · NA · enrolling by invitation
- NCT06912269 — Effects of Strength Training on the Plantar Flexors' Properties After Achilles Tendon Rupture · NA · recruiting
- NCT06416046 — Efficacy of Photobiomodulation in the Treatment and Relief of Pain in Recurrent Aphthous Stomatitis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03543488 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Federal University of Rio Grande do Sul
- Last refreshed: 1 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03543488.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing